1. Home
  2. MFIC vs TBPH Comparison

MFIC vs TBPH Comparison

Compare MFIC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MidCap Financial Investment Corporation

MFIC

MidCap Financial Investment Corporation

HOLD

Current Price

$11.38

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$19.65

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFIC
TBPH
Founded
2004
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
993.7M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
MFIC
TBPH
Price
$11.38
$19.65
Analyst Decision
Hold
Strong Buy
Analyst Count
6
5
Target Price
$12.63
$27.80
AVG Volume (30 Days)
833.1K
505.0K
Earning Date
02-24-2026
02-25-2026
Dividend Yield
13.25%
N/A
EPS Growth
N/A
N/A
EPS
1.07
0.58
Revenue
$324,678,000.00
$80,327,000.00
Revenue This Year
$9.15
$70.78
Revenue Next Year
N/A
N/A
P/E Ratio
$10.73
$32.83
Revenue Growth
11.35
27.12
52 Week Low
$10.18
$7.90
52 Week High
$14.74
$20.33

Technical Indicators

Market Signals
Indicator
MFIC
TBPH
Relative Strength Index (RSI) 43.48 64.36
Support Level $11.04 $17.59
Resistance Level $11.65 $19.25
Average True Range (ATR) 0.22 0.59
MACD 0.00 0.04
Stochastic Oscillator 44.44 95.00

Price Performance

Historical Comparison
MFIC
TBPH

About MFIC MidCap Financial Investment Corporation

MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: